TickerFacts.

Alpha Cognition Inc. (ACOG): Cash & Equivalents

Annual figures by period end, from SEC filings.

$66.05M
As of 2025-12-31
$41.38M
As of 2026-06-30
2023-12-31: $1.40M2024-12-31: $48.55M2025-12-31: $66.05M$66.05M
2023-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$66.05M+36.0%2026-03-31, Balance as of period end
2024-12-31$48.55Mn/m2026-03-31, Balance as of period end
2023-12-31$1.40Mn/a2025-03-31, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Alpha Cognition Inc. (ACOG)2025-12-31$66.05M+36.0%
TScan Therapeutics, Inc. (TCRX)2025-12-31$152.41M-14.7%
Taysha Gene Therapies, Inc. (TSHA)2025-12-31$319.77M+130.0%
Curis Inc (CRIS)2025-12-31$5.06M-74.7%
Caribou Biosciences, Inc. (CRBU)2025-12-31$12.36M-24.1%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$40.79M-10.9%
Relay Therapeutics, Inc. (RLAY)2025-12-31$84.02M-32.4%
Fate Therapeutics Inc (FATE)2025-12-31$46.63M+29.3%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$17.97Mn/m

Compare ACOG, TCRX, TSHA, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗